What is Acurx Pharmaceuticals, Inc.'s earnings per share (EPS)?

Acurx Pharmaceuticals, Inc. (ACXP) reported diluted earnings per share of -$5.32 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Acurx Pharmaceuticals, Inc. (ACXP) Financials

ACXP

FY2025 annual

Revenue Not reported for FY2025

Net Income -$8.0M +43.5% YoY

EPS (Diluted) -$5.32 YoY not available

Operating Cash Flow -$6.8M +34.6% YoY

Market Cap $6.4M as of Oct 14, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.8x on $8.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACXP SEC filings page.

This page shows Acurx Pharmaceuticals, Inc. (ACXP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ACXP FY2025 2026-10-03

Reported results describe a pre-revenue business funded by outside capital, with 2025 losses and cash use easing but not disappearing.

In 2025, net loss narrowed to $8.0M while operating cash flow was -$6.8M, so accounting losses translated into similarly sized cash use. That relationship was closer than in 2024, indicating improved earnings quality rather than a purely accounting improvement.

Outside financing remained the practical funding source: financing cash flow was $10.6M against operating cash flow of -$6.8M in 2025. The supplied liquidity measure was 13.4 months of reported annual outflow, reinforcing that available cash resources were being assessed alongside external funding rather than revenue.

Assets reached $7.7M while liabilities were $2.4M, a stronger balance-sheet position than the prior year. That left reported equity at $5.3M, versus $0.6M in 2024, giving the company more balance-sheet cushion despite ongoing losses.

Financial Health Signals

Financial health score not available

Acurx Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/5

Acurx Pharmaceuticals, Inc. passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Acurx Pharmaceuticals, Inc. reported a net loss of $8.0M while operations used $6.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$2.3M

YoY-0.4%

QoQ-34.1%

Acurx Pharmaceuticals, Inc. reported -$2.3M in net income in Q2 2026. This represents a decrease of 0.4% from the same quarter a year earlier. Against the prior quarter it is down 34.1%.

EPS (Diluted)

-$0.53

Acurx Pharmaceuticals, Inc. earned -$0.53 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$10.7M

YoY+75.7%

QoQ+15.1%

5Y CAGR-9.0%

Acurx Pharmaceuticals, Inc. held $10.7M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

5Y CAGR-12.2%

Acurx Pharmaceuticals, Inc. had 5M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-27.7%

YoY+35.3pp

QoQ-3.7pp

Acurx Pharmaceuticals, Inc.'s ROE was -27.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 35.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.7 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.1M

YoY+104.4%

QoQ+213.8%

Acurx Pharmaceuticals, Inc. invested $1.1M in research and development in Q2 2026. This represents an increase of 104.4% from the same quarter a year earlier. Against the prior quarter it is up 213.8%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

ACXP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ACXP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
R&D Expenses	N/A	$1.8M-66.1%	$5.4M-10.6%	$6.0M+27.1%	$4.8M+134.2%	$2.0M-7.8%	$2.2M
SG&A Expenses	N/A	$6.3M-28.2%	$8.7M+2.2%	$8.5M+16.3%	$7.3M+3423.6%	$208K-91.3%	$2.4M
Operating Income	N/A	-$8.1M+42.7%	-$14.1M	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	$0	N/A	$0
Net Income	N/A	-$8.0M+43.5%	-$14.1M+3.3%	-$14.6M-20.5%	-$12.1M+5.1%	-$12.7M-177.1%	-$4.6M
EPS (Basic)	N/A	-$5.32+69.5%	-$17.45-1417.4%	-$1.15-2.7%	-$1.12+24.8%	-$1.49-101.4%	-$0.74
EPS (Diluted)	—	-$5.32	-$17.45	-$1.15-2.7%	-$1.12+24.8%	-$1.49-101.4%	-$0.74
Diluted Shares (Avg)	N/A	1M	808,168	13M+17.2%	11M+26.7%	9M+37.9%	6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$1.1M+104.4%	$341K-43.0%	N/A	$430K-64.1%	$524K-71.3%	$599K-61.5%	N/A	$1.2M-11.2%
SG&A Expenses	$1.2M-29.2%	$1.4M-12.9%	N/A	$1.6M-1.8%	$1.7M-24.0%	$1.6M-44.1%	N/A	$1.6M-7.8%
Operating Income	-$2.3M-1.7%	-$1.7M+21.2%	N/A	-$2.0M+28.2%	-$2.3M+44.9%	-$2.2M	N/A	-$2.8M
Net Income	-$2.3M-0.4%	-$1.7M+21.8%	N/A	-$2.0M+29.4%	-$2.2M+45.5%	-$2.1M+50.9%	N/A	-$2.8M+9.4%
EPS (Basic)	-$0.53+72.0%	-$0.62+71.2%	-$0.31+90.4%	-$1.23+64.3%	-$1.89+63.7%	-$2.15-667.9%	-$3.22-747.4%	-$3.45-1337.5%
EPS (Diluted)	-$0.53	-$0.62	-$0.31	-$1.23	-$1.89	-$2.15	-$3.22-747.4%	-$3.45
Diluted Shares (Avg)	4M	3M	N/A	2M	1M	1M	N/A	818,174

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.

ACXP Balance Sheet

ACXP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$7.7M+99.3%	$3.9M-50.0%	$7.7M-17.8%	$9.4M-29.3%	$13.3M+311.1%	$3.2M
Current Assets	N/A	$3.9M-50.0%	$7.7M-17.8%	$9.4M-29.3%	$13.3M	N/A
Cash & Equivalents	$7.6M+103.8%	$3.7M-50.4%	$7.5M-18.0%	$9.1M-29.7%	$13.0M+308.1%	$3.2M
Short-Term Investments	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.4M-25.3%	$3.2M+6.6%	$3.0M+47.6%	$2.1M+144.3%	$844K+61.5%	$522K
Current Liabilities	$2.4M-25.3%	$3.2M+6.6%	$3.0M+47.6%	$2.1M+144.3%	$844K+78.6%	$473K
Non-Current Liabilities	$0	$0	$0	$0	$0-100.0%	$50K
Total Equity	$5.3M+756.5%	$615K-86.8%	$4.7M-36.2%	$7.3M-41.1%	$12.4M+359.4%	$2.7M
Retained Earnings	-$75.3M-11.8%	-$67.3M-26.5%	-$53.2M-37.7%	-$38.6M-45.6%	-$26.5M-92.4%	-$13.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$11.0M+78.4%	$9.5M+98.5%	$7.7M+99.3%	$6.1M+2.0%	$6.2M-6.4%	$4.8M-47.2%	$3.9M-50.0%	$6.0M-16.4%
Current Assets	N/A	N/A	N/A	N/A	$6.2M	$4.8M	$3.9M-50.0%	$6.0M-16.4%
Cash & Equivalents	$10.7M+75.7%	$9.3M+99.3%	$7.6M+103.8%	$5.9M+2.5%	$6.1M-4.7%	$4.6M-47.9%	$3.7M-50.4%	$5.8M-18.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.8M+9.3%	$2.5M+1.3%	$2.4M-25.3%	$2.5M-25.6%	$2.6M-17.8%	$2.5M-19.8%	$3.2M+6.6%	$3.3M+3.0%
Current Liabilities	$2.8M+9.3%	$2.5M+1.3%	$2.4M-25.3%	$2.5M-25.6%	$2.6M-17.8%	$2.5M-19.8%	$3.2M+6.6%	$3.3M+3.0%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$8.2M+128.6%	$7.0M+203.4%	$5.3M+756.5%	$3.6M+36.5%	$3.6M+4.1%	$2.3M-61.5%	$615K-86.8%	$2.7M-32.3%
Retained Earnings	-$79.2M-10.5%	-$77.0M-10.8%	-$75.3M-11.8%	-$73.7M-14.2%	-$71.7M-16.2%	-$69.5M-20.6%	-$67.3M-26.5%	-$64.5M-34.2%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ACXP Cash Flow Statement

ACXP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$6.2M	-$6.8M+34.6%	-$10.4M-5.9%	-$9.8M-29.9%	-$7.5M-50.4%	-$5.0M-49.6%	-$3.4M
Stock-Based Compensation	N/A	$1.2M-52.1%	$2.6M-18.9%	$3.2M+11.7%	$2.9M-44.3%	$5.2M+640.8%	$696K
Financing Cash Flow	$10.8M	$10.6M+60.8%	$6.6M-19.0%	$8.2M+120.9%	$3.7M-75.0%	$14.8M+265.9%	$4.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.7M-2.4%	-$1.4M+31.4%	-$1.2M+47.4%	-$1.9M+14.1%	-$1.7M+42.0%	-$2.1M+33.0%	-$2.3M+46.4%	-$2.2M-4.6%
Stock-Based Compensation	N/A	$258K-22.6%	N/A	N/A	N/A	$334K-62.7%	N/A	N/A
Financing Cash Flow	$3.1M+0.7%	$3.1M+3.9%	$2.8M+1356.7%	$1.7M+8.3%	$3.1M+865.2%	$3.0M-33.7%	$195K-95.8%	$1.6M

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

ACXP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ACXP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Return on Equity	-151.2%+2141.5pp	-2292.7%-1980.4pp	-312.4%-147.1pp	-165.3%-62.6pp	-102.7%+67.6pp	-170.3%
Return on Assets	-103.6%+262.0pp	-365.6%-176.5pp	-189.1%-60.1pp	-129.0%-32.8pp	-96.2%+46.5pp	-142.7%
Current Ratio	N/A	1.19-1.3x	2.53-2.0x	4.55-11.2x	15.71	N/A
Debt-to-Equity	0.46-4.8x	5.27+4.6x	0.65+0.4x	0.28+0.2x	0.07-0.1x	0.19

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-27.7%+35.3pp	-24.0%+69.0pp	N/A	-54.8%+51.1pp	-63.0%+57.3pp	-93.0%-20.0pp	N/A	-105.9%-26.7pp
Return on Assets	-20.5%+16.0pp	-17.6%+27.1pp	N/A	-32.6%+14.5pp	-36.5%+26.2pp	-44.7%+3.3pp	N/A	-47.2%-3.6pp
Current Ratio	N/A	N/A	N/A	N/A	2.38	1.93	1.19-1.3x	1.80-0.4x
Debt-to-Equity	0.35-0.4x	0.36-0.7x	0.46-4.8x	0.68-0.6x	0.73-0.2x	1.08+0.6x	5.27+4.6x	1.25+0.4x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Acurx Pharmaceuticals, Inc. ACXP	FY2025	N/A	-$8.0M	N/A	$6.4M	—
Artelo Biosciences, Inc. ARTL	FY2025	N/A	-$12.9M	N/A	$1.6M	—
TNF Pharmaceuticals, Inc. TNFA	FY2025	N/A	-$11.6M	N/A	$9.6M	—
AIM ImmunoTech Inc. AIM	FY2025	$88K	-$14.0M	N/A	$6.8M	—
PharmaCyte Biotech, Inc. PMCB	FY2026	$0	-$19.4M	N/A	$3.8M	—

Where Acurx Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

Is Acurx Pharmaceuticals, Inc. profitable?

No, Acurx Pharmaceuticals, Inc. (ACXP) reported a net income of -$8.0M in fiscal year 2025.

What is Acurx Pharmaceuticals, Inc.'s return on equity (ROE)?

Acurx Pharmaceuticals, Inc. (ACXP) has a return on equity of -151.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Acurx Pharmaceuticals, Inc.'s operating cash flow?

Acurx Pharmaceuticals, Inc. (ACXP) recorded an outflow of $6.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Acurx Pharmaceuticals, Inc.'s total assets?

Acurx Pharmaceuticals, Inc. (ACXP) had $7.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Acurx Pharmaceuticals, Inc. spend on research and development?

Acurx Pharmaceuticals, Inc. (ACXP) invested $1.8M in research and development during fiscal year 2025.

How many shares does Acurx Pharmaceuticals, Inc. have outstanding?

Acurx Pharmaceuticals, Inc. (ACXP) had 3M shares outstanding as of fiscal year 2025.

What is Acurx Pharmaceuticals, Inc.'s debt-to-equity ratio?

Acurx Pharmaceuticals, Inc. (ACXP) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Acurx Pharmaceuticals, Inc.'s return on assets (ROA)?

Acurx Pharmaceuticals, Inc. (ACXP) had a return on assets of -103.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Acurx Pharmaceuticals, Inc.'s P/E ratio?

Acurx Pharmaceuticals, Inc. (ACXP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $6.4M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Acurx Pharmaceuticals, Inc.'s price-to-sales ratio?

Acurx Pharmaceuticals, Inc. (ACXP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $6.4M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Acurx Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Acurx Pharmaceuticals, Inc. (ACXP) held $7.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.8M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Acurx Pharmaceuticals, Inc.'s Piotroski F-Score?

Acurx Pharmaceuticals, Inc. (ACXP) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Acurx Pharmaceuticals, Inc.'s earnings high quality?

Acurx Pharmaceuticals, Inc. (ACXP) reported a net loss of $8.0M while operations used $6.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.